RPL32P25

Across TCGA pan-cancer cohorts, RPL32P25 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of RPL32P25’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RPL32P25 RNA is repressed in tumor relative to normal tissue. In most cancer types RPL32P25 is over-expressed in tumor, although a few such as BRCA and LUSC show the opposite, repressed pattern.

BRCA, LUSC, and ESCA are the cancer types where RPL32P25 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL32P25 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	II,III,IV	−0.235	<.001	6	view →
LUSC	All	All	−0.078	.008	2	view →
ESCA	Female	All	+0.160	.016	1	view →
LUAD	Female	II,III,IV	−0.140	.027	1	view →
THCA	Female	II,III,IV	−0.111	.047	1	view →
KIRC	Female	All	+0.086	.048	1	view →
KICH	All	All	−0.067	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

RPL32P25–BRCA

Open the BRCA breakdown →